Bernd C Kieseier
Overview
Explore the profile of Bernd C Kieseier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
257
Citations
6014
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mausberg A, Szepanowski F, Eggert B, Liebig K, Kleinschnitz C, Kieseier B, et al.
Immunol Res
. 2024 Dec;
73(1):12.
PMID: 39674966
The inhibition of the neonatal Fc receptor (FcRn) is a promising therapeutic pathway in certain autoimmune disorders to reduce the amount of circulating pathogenic IgG autoantibodies by interfering with their...
2.
Ocampo A, Hatami F, cuklina J, Graham G, Ganjgahi H, Sun Y, et al.
Mult Scler
. 2024 Sep;
30(11-12):1455-1467.
PMID: 39340359
Background: The long-term disease trajectory of people living with multiple sclerosis (MS) can be improved by initiating efficacious treatment early. More quantitative evidence is needed on factors that affect a...
3.
Fox R, Cree B, De Seze J, Gold R, Hartung H, Jeffery D, et al.
Neurology
. 2024 Apr;
102(9):e209357.
PMID: 38648580
Background And Objectives: Serum neurofilament light chain (sNfL) levels correlate with multiple sclerosis (MS) disease activity, but the dynamics of this correlation are unknown. We evaluated the relationship between sNfL...
4.
Airas L, Bermel R, Chitnis T, Hartung H, Nakahara J, Stuve O, et al.
Ther Adv Neurol Disord
. 2024 Apr;
17:17562864241233041.
PMID: 38638671
Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells,...
5.
Sominanda A, Menge T, Hartung H, Kieseier B
Qatar Med J
. 2023 Nov;
2023(2):13.
PMID: 38025317
Multiple sclerosis (MS) is a disabling neurological disease with an unknown etiology, where the recombinant interferon beta (rIFNβ) is the most established treatment. However, the development of anti-IFNβ antibodies has...
6.
Klehmet J, Tackenberg B, Haas J, Kieseier B
BMC Neurol
. 2023 May;
23(1):207.
PMID: 37237267
Introduction/aims: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patient's ability to walk and perform activities of daily living independently. Furthermore, patients often...
7.
Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, et al.
Neurol Ther
. 2022 Dec;
12(1):303-317.
PMID: 36534274
Introduction: Several studies have described prognostic value of serum neurofilament light chain (sNfL) at the group level in relapsing multiple sclerosis (RMS) patients. Here, we aimed to explore the temporal...
8.
Yu H, Graham G, David O, Kahn J, Savelieva M, Pigeolet E, et al.
CNS Drugs
. 2022 Mar;
36(3):283-300.
PMID: 35233753
Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS), binds to a unique conformational epitope, thereby depleting B cells very...
9.
Hauser S, Cross A, Winthrop K, Wiendl H, Nicholas J, Meuth S, et al.
Mult Scler
. 2022 Mar;
28(10):1576-1590.
PMID: 35229668
Background: Ofatumumab is approved for the treatment of relapsing multiple sclerosis (RMS). Ongoing safety reporting is crucial to understand its long-term benefit-risk profile. Objective: Report the safety and tolerability of...
10.
Lublin F, Haring D, Ganjgahi H, Ocampo A, Hatami F, cuklina J, et al.
Brain
. 2022 Feb;
145(9):3147-3161.
PMID: 35104840
Patients with multiple sclerosis acquire disability either through relapse-associated worsening (RAW) or progression independent of relapse activity (PIRA). This study addresses the relative contribution of relapses to disability worsening over...